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1. ABSTRACT
Here we critically review studies that used 
electroencephalography (EEG) or event-related 
potential (ERP) indices as a biomarker of Alzheimer’s 
disease. In the first part we overview studies that 
relied on visual inspection of EEG traces and spectral 
characteristics of EEG. Second, we survey analysis 
methods motivated by dynamical systems theory 
(DST) as well as more recent network connectivity 
approaches. In the third part we review studies of 
sleep. Next, we compare the utility of early and late 
ERP components in dementia research. In the section 
on mismatch negativity (MMN) studies we summarize 
their results and limitations and outline the emerging 
field of computational neurology. In the following we 
overview the use of EEG in the differential diagnosis 
of the most common neurocognitive disorders. Finally, 
we provide a summary of the state of the field and 
conclude that several promising EEG/ERP indices of 
synaptic neurotransmission are worth considering as 
potential biomarkers. Furthermore, we highlight some 
practical issues and discuss future challenges as well.
2. INTRODUCTION
Alzheimer’s disease is the most common 
cause of cognitive decline in the elderly creating 
significant medical and economic burden. 
Approximately 47 millions of people live with 
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neurocognitive disorders worldwide, and this number 
is expected to triple by 2050 (1). Despite the huge 
efforts to find accurate treatment for AD, we are still not 
able to influence the progression of the disease. One 
of the reasons for this failure is that the pathological 
changes start decades before the initial clinical 
symptoms (2). The neuropathological hallmarks of 
AD are the presence of extracellular amyloid plaques 
and the intracellular neurofibrillary tangles composed 
of hyperphosphorylated tau protein. Growing body 
of evidence (3) suggests that the misfolded proteins 
might compromise the synaptic functions leading 
to severe network disintegration. Recent studies 
have illustrated that abnormal tau and amyloid 
could modify the pre- and postsynaptic neuronal 
mechanisms, elevate the neuronal calcium influx 
leading to increased excitability, neuronal loss and 
altered rhythmic patterns (4–6). Synaptic plasticity is 
essential in all complex cognitive functions such as 
learning, abstract thinking and memory (7). Evidence 
from recent neurophysiological and pathological 
studies suggests that impaired synaptic plasticity 
is a dominant feature of AD (8). Intact synaptic 
plasticity seems to be essential to normal neuronal 
oscillatory synchronization, which is thought to be the 
basis of information transfer at cell population level 
in the human brain underlying cognitive functions 
by functionally integrating a distributed network 
neuronal populations (9). Only recently, we begin to 
see how compromised network functions may affect 
motor activity, perception, or more complex cognitive 
functions like memory formation or decision-making. 
The emerging view of neurological and psychiatric 
disorders as ‘‘oscillopathies’’ provides a new 
perspective that might help better understand clinical 
conditions (10). Based on these considerations, 
AD has recently been described as a network 
disconnection disease or as an oscillopathy (11).
Large-scale oscillatory neural population 
activity and event-related responses are often 
recoded using electroencephalography (EEG). EEG 
is a relatively cost-effective, non-invasive technique 
that provides in vivo data on electrical activity during 
neurotransmission with high temporal resolution. EEG 
has been successfully used in studying neurocognitive 
disorders, for example in schizophrenia (12), which 
has also been conceptualized as a dysconnection 
syndrome (13–14). Several characteristics of the 
EEG and event-related potentials (ERP) have been 
put forward as biomarkers in AD (15). Biomarkers are 
objective indicators of medical state that are sensitive 
and specific to a given pathology (16). Although a 
growing body of evidence indicates that EEG might be 
useful in the early recognition of neural signatures of 
dementia (17) as well as in the differential diagnosis of 
cognitive impairment (15, 18), this technique is rarely 
involved in the protocols of clinical assessment of 
cognitive decline.
Here we summarize the current knowledge 
on potential EEG and ERP biomarkers with respect 
to their importance in the diagnosis of AD, in early 
recognition of cognitive impairment, in differential 
diagnosis of neurocognitive disorders, and their relation 
to neuroimaging and neuropsychological findings.
3. EEG STUDIES IN AD
3.1. Visual inspection and spectral characteristics 
of EEG in AD
The conventional visual inspection of the EEG 
is still a widely used diagnostic method of neurological 
assessment (e.g., 19). The disappearance of posterior 
dominant alpha rhythm and the diffuse slowing in AD 
are easily detectable EEG signs for the experienced 
eyes. These changes have been reported in numerous 
previous studies even in patients with pathologically 
confirmed diagnosis (35 AD patients in the study of 
Brenner et al., (20)) and 72 patients in the study of 
Gordon et al., (21)). Strong correlation between visual 
EEG scores and dementia severity assessed by Mini 
Mental State Examination (MMSE) has been reported 
(22–23). In the study of de Waal et al. with 460 AD 
patients, subjects with early onset AD presented 
more severe diffuse slowing compared to the later 
onset counterparts, which is in line with the clinical 
presentation of AD (23). Based on these findings, the 
visual inspection of the EEG seems to be useful in the 
evaluation of AD.
Spectral analysis of EEG signals by Fourier 
or wavelet transformation has been widely used 
in the research of neurological and psychiatric 
disorders, including cerebrovascular disorders and 
epilepsy. Originally, the method was suggested by 
Roy John with the aim of the differential diagnosis of 
brain dysfunctions (24). Spectral methods estimate 
the power of selected EEG frequency bands, and 
the results are often evaluated with regard to their 
topographical distribution. Early spectral EEG studies 
revealed that a shift to lower frequency rhythms, i.e., 
a diffuse slowing of the EEG is a prominent feature 
of AD. Specifically, a reduction of power in the alpha 
(8–15Hz) and beta (16–31Hz) bands, as well as an 
increase in the theta (4–8Hz) and delta (0.5–4Hz) 
bands have been observed (25–26). Studies on higher 
frequency brain activity such as gamma oscillations 
yielded conflicting results (11). While Stam and 
his colleagues reported the loss of gamma band 
synchronization using magnetoencephalography 
(MEG) (27), other EEG (28–29) and MEG (30) studies 
found an increase in gamma power. Some studies 
indicate that in the diagnosis of AD the measurement of 
theta power could be as sensitive as the measurement 
of regional glucose metabolism by PET. In the studies 
of Szelies on 24 AD patients, the differentiation of AD 
and age matched healthy elderly using relative theta 
EEG and ERP biomarkers in AD
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power was correct in 86% while it was correct in 87% 
when assessing temporo-parietal glucose metabolism 
(31–32).
It has also been shown that spectral changes 
show specific topographical distribution. Earlier studies 
with low sample size (12 and 8 AD patients) reported 
that the increase of lower frequency bands typically 
appeared over the left temporal area (33–34). The 
difference between mild AD and normal healthy controls 
seemed to be the most prominent in the temporal area, 
while comparing advanced AD patients with controls 
the difference was mainly related to the mid-frontal 
and anterior bifrontal areas (35). In a study involving 
higher number of patients (n=48) using low resolution 
brain electromagnetic tomography (LORETA), Babiloni 
and his colleagues demonstrated that patients with mild 
AD had a significant attenuation in the low alpha band 
in temporo-parietal and limbic sources compared to 
age-matched normal individuals (36). In the experiment 
of Kwak (37), the left anterior alpha power was lower 
in patients with a Clinical Dementia Rating Scale 
(CDR) value of 0.5, compared to cognitively normal 
elderlies. In CDR the 0 value represents the normal 
population, the 0.5 is very mild dementia, 1 is mild 
dementia, and 2 is moderate dementia, while 3 means 
severe dementia. Posterior theta power was increased 
bilaterally and power in all alpha bands was reduced 
in CDR 1 patients; while all alpha and beta power was 
reduced and the theta spectral power was increased in 
the CDR 2 patients; and alpha and beta spectral power 
was reduced and delta and theta spectral power was 
increased in the CDR 3 group (37). These changes are 
in line with the well-known pathological progression of 
the misfolded protein aggregation (38) suggesting that 
spectral alterations might indicate the severity of the 
disease (39).
Numerous studies with great samples have 
reported that spectral EEG measures showed a 
relationship to scores on common neuropsychological 
tests assessing cognitive functions. Significant 
correlation was revealed between the results of MMSE, 
Global Deterioration Scale (GDS), Addenbrooke 
Cognitive Examination (ACE) and qEEG parameters 
such as occipital peak frequency, reduction of alpha 
and beta spectral powers and increase in theta and 
delta spectral powers (37). In 69 subjects with mild 
cognitive impairment (MCI) and AD the delta power 
negatively correlated with MMSE scores, while 
alpha power showed a positive correlation (40). 
The decrease in alpha power was also found to be 
correlated with scores in the Cognitive Subscale of the 
Alzheimer’s Disease Assessment Scale (ADAS-Cog) 
in a study with 130 patients (41). In the experiment 
of Claus et al. involving 82 patients, Cambridge 
Cognition Examination (CAMCOG) scores showed 
similar results (42). Only one early study reported a 
minimal or no correlation between the EEG and the 
neuropsychological test results; however, this study 
examined dementia patients with different etiology 
including AD, frontotemporal dementia, multi-infarct 
dementia and alcoholic dementia patients. (43).
Correlations between EEG changes and 
neuroimaging findings have been reported in many 
studies as well. Global alpha and delta power showed 
a relationship to the volumetric changes of sub-cortical 
white matter in a study with 65 AD and 34 MCI patients 
(44), to the level of hippocampal atrophy in 35 AD and 
88 MCI patients (45), to the grey matter density of the 
thalamus and basal ganglia in 88 MCI patients (46) 
and to the volume of cortical grey matter in 108 AD 
and 102 MCI patients (47). In an earlier study, qEEG 
(prominently the relative theta power) could predict 
dementia severity with similar power as PET markers 
(32). The combination of MRI, PET, P300 EEG 
analysis and spectral EEG power analysis increased 
the accuracy of dementia diagnosis by 10–20% 
compared to a single diagnostic method (48). These 
findings indicate that qEEG might be useful to assess 
the severity and progression of AD (49).
Pathologic changes in AD are generally 
assumed to start several years before initial symptoms 
of cognitive deterioration appear (50). There is an 
urgent need to identify the disease in the prodromal 
or in the early clinical phases such as MCI. To address 
this, Jelic et al. studied spectral EEG properties in 
27 MCI and 15 AD patients and found that the MCI 
group did not differ from the healthy controls in the 
baseline EEG measures. However, MCI patients 
had significantly lower relative theta power at the left 
temporal, temporo-occipital, centro-parietal and right 
temporo-occipital derivation compared to the AD group 
(50). In other studies with larger samples (69 MCI, 73 
AD, and 64 control subjects), an increase in the relative 
theta-power and a decrease in alpha indicated well the 
conversion of MCI to AD. In LORETA studies, patients 
with MCI exhibited a reduction in centro-temporal, 
posterior delta and left anterior theta fields (51). In 
another study the same group found that amnesic 
MCI patients represent an intermediate stage between 
normal cognition and mild AD based on parietal and 
occipital power in the low alpha frequency band (47). A 
study by Huang et al. with 38 AD, 31 MCI and 24 control 
participants reported an anterior shift of the maximum 
alpha and beta power in AD compared to MCI (52). 
Based on longitudinal studies with 39 patients, the 
increase of delta and theta power and the decline in 
the alpha and beta band power are the most important 
predictors of conversion from MCI to AD within 1- and 
2-year follow-ups (53–54). EEG studies have also 
showed differences in genetic mutation carriers of AD 
without memory complaints compared to non-carriers. 
Studies revealed that there is no difference between 
the apoE carriers and normal individuals; however, the 
presence of an apoε4 allele was associated with the 
EEG and ERP biomarkers in AD
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manifestation of synchronous high-voltage delta and 
theta activity as well as sharp-waves. Furthermore, 
hyperventilation induced significantly higher decrease 
in the alpha power and increase in delta-theta relative 
powers by the carriers in the studies of Ponomareva 
and colleagues involving altogether 572 individuals 
(55–58). Another study with 118 patients illustrated 
that apoε4 carriers show more frequent focal or 
global irregular slow wave activities after a traumatic 
brain injury (59). Interestingly, a recent study with 
lower number of participants revealed that patients 
(n=21) with presenilin-1 mutation show a significant 
decrease of the fast frequency bands prominently in 
the temporal regions compared to non-carriers even in 
the asymptomatic phase (60). These studies suggest 
that markers based on spectral EEG measures could 
be useful in the early identification of AD.
EEG studies on AD patients revealed that 
decrease in alpha power and increase in delta are 
the most prominent features of Alzheimer’s disease, 
showing a strong relationship to neuropsychological 
test results (40–42) and structural brain alterations (44–
47). Spectral changes in the delta and alpha band also 
indicate the conversion of MCI to AD (51). Theta power 
increase has also been suggested as a predictor for 
conversion of MCI to AD (51, 53). Reduced beta power 
has been reported in AD suggesting that it might be 
useful in the monitoring of MCI-AD conversion as well 
(37, 52). The changes of gamma band in AD and MCI 
are still ambiguous (27–30). These alterations together 
underlie the typical visual EEG appearance of AD, the 
diffuse slowing (23).
Simple measures of power at different 
frequencies fail to capture one of the most 
important features of the EEG signal, namely the 
dynamic coupling between the different oscillating 
populations. However, cognitive functions are 
supported by dynamic interactions between 
spatially separated but temporally coordinated brain 
networks. After the introduction of the disconnection 
theory by Delbeuck and his coworkers to dementia 
research, methods focusing on the measurement 
of functional connectivity between distributed brain 
areas have been applied more frequently in the 
field (61). The theoretical assumptions underlying 
these measurements is that rhythmic EEG activity in 
resting state reflect phase and/or amplitude coupling 
of oscillations in different neuronal populations. 
Such measures provide information about functional 
integration and segregation between oscillating 
populations, captured by synchrony between the 
EEG signals recorded at various electrode pairs 
(62). Spectral coherence is thought to indicating 
functional coordination between two or more EEG 
generators (63). For example, higher coherence 
values have been observed between brain regions 
with higher interactions and stronger associations 
during perceptual and motor processes (64). It has 
been postulated that cholinergic pathways play an 
organizing function and modulate coherence across 
distant brain areas (65). It is strongly supported 
by a study demonstrating that scopolamine with 
anticholinergic effect reduces the EEG coherence 
(66). Because of the structural damage of the 
generators and the involvement of cholinergic 
basal forebrain neurons in AD (67), coherence 
studies pointed out significant alterations. Major 
decrease in coherence in the alpha band has been 
demonstrated in several studies, particularly at the 
left temporal region (n=31 AD patients) (68), with 
significant correlation to neuropsychological results 
(n=34 AD patients) (69). Delta coherence studies 
revealed conflicting results (68), but a recent study 
by Babiloni and his colleagues showed that AD 
patients have higher delta ant theta coherence 
than normal controls (45). Global theta coherence 
increase was demonstrated in the study of Adler 
et al., but the interhemispheric theta coherence 
was significantly reduced (68). It should be noted 
that elevated delta coherence was also observed in 
MCI patients but in a lower extent compared to AD 
patients (70).
In summary, spectral power and coherence 
in different frequency bands might offer promising 
clinical tools for diagnosing AD, assessing the severity 
of cognitive decline, and they might contribute to early 
disease recognition (Table 1).
3.2. Non-linear EEG studies in AD
The basic concept of non-linear time series 
analysis of EEG rests on the assumption that the brain 
is a non-linear dynamical system thus its behavior 
follows the principles of chaos theory (71). EEG 
captures the large-scale spatio-temporal dynamics of 
electromagnetic fields in the brain which are thought 
to be generated by non-linear coupling interactions 
between different neuronal populations. According to 
Stam the trajectory of a non-linear dynamical system 
is determined by its initial state and the history of 
its evolution. It can be argued that such a system 
possesses memory since its current state is dependent 
on previous states (62). The first studies on non-linear 
dynamical properties of EEG have been published in 
the 80’s and focused on primate spontaneous EEG 
and human sleep EEG (72). In the following years, 
a revolution took place in the field of non-linear EEG 
analysis focusing on modeling non-linear neuronal 
dynamics and on the development of new methods 
with the aim to analyze noisy, non-stationary and high-
dimensional EEG. Numerous methods have been 
developed including non-linear forecasting, non-linear 
cross prediction, and dimension density; many of the 
novel methods relied on embedding the EEG time 
series in a multidimensional state-space and observing 
EEG and ERP biomarkers in AD
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different properties of resulting trajectories. For an 
exhaustive review see Stam (62).
It is well known that the pathological changes 
in AD affect not only specific brain regions but neural 
pathways between the major areas as well (73). Non-
linear methods are commonly used in the research 
of AD comparing it to other psychiatric conditions, 
because of the widely accepted disconnection 
syndrome theory (59).
Correlation dimension (D2) is one of the 
most commonly used non-linear EEG parameter 
in AD research. D2 is a measure of the assumed 
independent variables that are required to precisely 
define the complexity of cortical dynamics reflected 
in the EEG signal. An early study with 21 AD and 29 
MCI patients has shown that AD patients have lower 
D2 values almost on every EEG channel suggesting 
a globally reduced complexity of the electric brain 
activity in AD (74). Normal elderly have significantly 
increased D2 values in eyes-open state compare to 
eyes-closed state, while the difference disappears 
in AD, suggesting the loss of brain reactivity to 
external stimuli in AD (75). Further studies pointed out 
decreased complexity even in eyes-closed state in 15 
AD patients compared to normal controls (76). These 
studies aimed to characterize the EEG in a global 
frequency range; however, the separate frequency 
bands are thought to represent different brain dynamic 
systems (26). Numerous studies investigated the 
complexity of EEG in different frequency ranges or 
multiple time scales. They identified higher D2 at higher 
frequency ranges in 20 AD (77) and 17 AD patients 
(78), while lower values have been demonstrated 
in the low frequencies. Yosimura and colleagues 
investigated mild AD patients with the so-called omega 
complexity method and found high complexity in a 
wide range of frequencies similarly to the findings of 
Czigler and colleagues involving 12 AD patients (78–
79). Omega complexity estimates the number of the 
independent, uncorrelated brain sources. Thus, these 
studies suggest the functional disintegration of cortical 
networks, with lower coherence between sources 
and a higher number of independent generators. A 
decrease in the parameter that reflects flexibility of 
information processing, the so-called first positive 
Lyupanov exponent (L1), has been also reported in 
some studies (27), which may represent a difficulty 
to enter different states from the initial one during 
information processing in AD.
Some new methods, such as multiscale 
entropy (MSE) have been implemented in the recent 
years enabling to investigate the complexity of 
dynamic biological signals across a long-range of 
temporal scales. These studies in 11 AD patients (80) 
as well as 26 AD and 22 MCI patients (81) found that 
AD patients had less complexity at smaller temporal 
scales related to higher frequency bands and higher 
complexity at larger temporal scales regarding lower 
frequency bands (80–81). Higher complexity in large 
temporal scales was strongly associated to the extent 
of cognitive decline. Studies of global range complexity 
yielded diverging results. However, different frequency 
bands correspond to different brain functions (82). 
While higher-frequency bands are thought to support 
local neuronal communication in smaller neuron 
groups with short-range neural connectivity, slower 
oscillations likely arise from larger populations 
within wider-range networks (83). Although finding a 
physiological interpretation of complexity measures 
obtained with methods motivated by dynamical system 
theory is not straightforward, these results are in line 
with the notion that AD is characterized by a disruption 
of integration and segregation within distributed brain 
networks (61).
Complexity measurements have 
shown a strong correlation also with results of 
neuropsychological tests. Lower global dimensional 
complexity was associated with lower MMSE scores 
in 21 AD patients (74). The estimated severity of the 
disease also showed a strong relationship to non-linear 
measures in the study of Besthorn involving 50 AD 
patients (84). Region-specific changes were observed 
in the study of Ikawa et al., where a strong association 
was found between the reduced dynamical complexity 
(DC) in the mid-temporal, left frontal, central areas and 
cognitive status in 25 AD patients (85). In the same 
 Table 1. Changes in spectral power and phase coherence of different EEG bands in AD, MCI and preclinical
stages of AD
EEG band Spectral power and phase coherence 
in AD
Spectral power and phase coherence 
in MCI
Spectral power and phase coherence 
in preclinical AD
Gamma IC IC DNA
Beta ↓↓ ↓↓↓ ↓↓
Alpha ↓↓↓ ↓↓↓ ↓↓↓
Theta ↑↑ ↑↑ ↑
Delta ↑↑↑ ↑↑ ↑↑↑
The number of arrows indicates the number of studies reporting concordant results: ↑ = 1–5 studies ↑↑ = 5–10 studies ↑↑↑ >10 studies. DNA = data not 
available; IC = inconclusive results.
EEG and ERP biomarkers in AD
188 © 1996-2018
study a correlation has been found also between 
verbal memory performance and DC values at post-
temporal, left-central and parietal regions. Interestingly, 
in the early phases of AD, increased predictability and 
reduced complexity are predominantly visible in frontal 
and temporal areas (76).
Using the relatively new measures of mutual 
information (MI) and synchronization likelihood (SL), 
it has been demonstrated that the interdependency 
between the distant electrodes, especially between the 
frontal and temporal regions, between the frontal and 
parietal and between the hemispheres are reduced 
(26). Significant decrease in the SL of beta and high 
alpha band was also indicated in the study of Stam 
with 24 AD patients, where SL of both frequency bands 
had a strong correlation to the MMSE scores (86), 
while the gamma band was not affected. Babiloni and 
his colleagues obtained similar results in MCI; namely 
they found reduced SL in the delta band in 109 AD 
and 88 MCI patients with fronto-parietal dominance 
(87). Phase lag index (PLI) measurements revealed 
frequency dependent results in 18 AD patients; in the 
theta band patients showed higher whole-brain PLI 
and in the alpha band lower whole-brain PLI compared 
to patients with subjective cognitive decline (88). 
Concluded minimum spanning trees (MSTs) analysis 
from PLI suggested that global efficiency loss was 
defined mostly by the parietal and occipital loss of 
network organization (89).
Overall, results suggest that earlier 
alterations in neural dynamics can be identified with 
spectral analysis methods which can identify more 
precisely the early stages of Alzheimer (75). However, 
the combination of spectral and state-space methods 
proved to be highly sensitive in the early recognition of 
cognitive decline (62).
New methods derived from the mathematical 
framework of graph theory have recently become 
popular in EEG analysis. Graph theory is used to 
describe network connectivity from EEG data. Nodes 
in the network often correspond to electrodes, and 
some measures of connectivity between electrode 
pairs are used to characterize edges (90). The 
nodes which receive more inputs and have more 
connections are referred to as hubs. Human 
cognition seems to be strongly related to the efficacy 
of the integration of different brain nodes. The normal 
human large-scale functional connectivity network 
can be described as a small-world network, with 
numerous local connections between adjacent nodes 
and a few but prominent connections between distant 
regions, which together lend high clustering and short 
path lengths to the network (91). Recent studies 
revealed that small-world like network properties of 
are replaced by random-world characteristics in AD. 
Studies demonstrated that AD patients (n=18) have a 
prominent decrease in the characteristic path length, 
degree correlation and mean clustering coefficient 
of delta and gamma band activity indicating severe 
loss in the local and global connectivity parameters 
(86,90). These findings were corroborated by MEG 
and fMRI studies as well including 18 (92), 20 (93), 
21 (94) and 14 AD patients (95).
In summary, current EEG network analysis 
methods provide a promising new strategy for the 
diagnosis of AD and studying disease progression, and 
open a fresh view to cognitive decline from a network 
based perspective. State-space approaches seem 
to be also promising tools for the early recognition of 
MCI, especially when combined with spectral methods 
(Table 2).
3.3. Sleep-EEG studies in AD
Major neurocognitive disorders including 
Alzheimer’s disease as well as MCI are characterized 
with disturbed sleep. Growing evidence suggests 
that sleep disturbances precede the clinical onset 
 Table 2. Different EEG analysis techniques motivated by dynamical systems theory show variable complexity
measures across studies in AD
Measured parameter Measured change Study and number of patients included
Correlation dimension (D2) Global decrease, increase in higher frequency bands, 
decrease in lower frequency bands 
Yagyu et al. (74), n=21 AD- 29 MCI patients
van Walsum et al. (77), n=20 AD patients
Yoshimura et al. (78), n=17 AD patients
Omega complexity (OC) Global increase Yoshimura et al. (78), n=17 AD patients
Czigler et al. (79), n=12 AD patients
Global complexity (GC) Global decrease Besthorn et al. (84), n=50 AD patients 
Multiscale entropy (MSE) Increase in higher frequency bands, decrease in lower 
frequency bands
Park et al. (81), n=26 AD- 22 MCI patients
Escudero et al. (80), n=11 AD patients 
Dynamical complexity (DC) Global decrease Ikawa et al. (85), n=25 AD patients 
While studies with spectral and other non-DST methods involve relatively large number of subjects, studies with non-linear methods are limited, recruit 
remarkably lower number of AD patients and show inconclusive results. DST methods might be useful for the early recognition of MCI; however, 
combination with other methods is recommended.
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of cognitive decline in AD by years. A sleep-wake 
disturbance of clinical importance is found in up to half 
of the patients with dementia, and sun-down agitation 
is a frequent cause of institutionalization of demented 
patients (96). The circadian rhythm of dementia 
patients is disturbed with daytime sleepiness and 
disrupted night sleep. Whereas sleep changes may 
be severe in several types of dementia, a clinically 
significant sleep disorder usually develops only in the 
late phase of Alzheimer’s disease (97-98).
Sleep transforms in many ways during healthy 
aging. Changes include reduction in the proportion of 
slow wave sleep (SWS) and sleep slow wave activity 
(SWA), the number and amplitude of sleep spindles 
as well as the density of rapid eye movements (REM) 
and the amplitude of circadian rhythms. With MCI 
there are further reductions of these parameters and 
all deteriorate further with the conversion to AD (99). 
Progressive changes in the quality, architecture and 
neural regulation of sleep may contribute to cognitive 
decline (100). The sleep profiles of patients with 
dementia of diffuse Lewy body and AD are different; 
which may have diagnostic importance (101).
Sleep pathology appears to be essential 
component of AD pathophysiology. Noticeably, sleep 
deprivation compromises cognitive and executive 
functions such as memory, attention, and response 
inhibition. In mice studies sleep deprivation impaired 
the mice’s long-term and remote memory, even a month 
after the sleep deprivation session (102). The negative 
impact of sleep loss on memory has also been shown 
in patients with sleep disorders. Impairments of sleep-
dependent memory consolidation for verbal and visual 
declarative information were found in patients with 
primary insomnia, for verbal declarative information in 
patients with obstructive sleep apnea, and for visual 
procedural skills in patients with narcolepsy-cataplexy 
(103). Conversely, increasing the amount of SWS and 
SWA by an anti-inflammatory agent in healthy humans 
improved memory consolidation (104). The positive 
cognitive effect of sleep slow waves was also shown 
in a transcranial slow oscillatory stimulation study 
where stimulation was applied during the afternoon 
naps of elderly individuals. The transcranial stimulation 
considerably increased frontal SWA significantly 
improving visual memory retention after sleep, but not 
retention in the location memory subtask and in the 
verbal memory task (105).
Changes in sleep microstructure have been 
observed as well in AD. Several studies have identified 
two types of sleep spindles: fast (13–15 Hz) centro-
parietal and slow (11–13 Hz) frontal spindles. AD and 
MCI patients have shown a significant decrease in 
parietal fast spindle density, which positively correlated 
with their loss in MMSE scores (106). Fast spindles 
are involved memory consolidation as enhancing 
sleep spindles with non-invasive brain stimulation 
in humans was found to significantly improve motor 
memory consolidation which correlated with the 
stimulation-induced increase of fast spindle activity 
(107).The impact of both slow and fast spindles on re-
presentation learning has been shown in an odor re-
exposure experiment (108).
Increased cerebrospinal fluid orexin levels 
were found causing sleep deterioration, which 
appeared to be associated with cognitive decline 
(109). The orexinergic system may be dysregulated 
in AD, while the role of orexin in memory function 
has remained controversial (110). Mice-experiments 
have shown an association of the amyloid-beta (Aβ) 
peptide and mitochondrial dysfunction, supporting 
a primary role for mitochondrial Aβ in AD pathology. 
Mitochondrial Aβ peptide levels were strongly 
negatively associated to the scores of cognitive tasks 
in an AD transgenic mice model experiment, indicating 
that amyloid could compromise the cognitive functions 
via the altered the mitochondrial signaling system. The 
degree of cognitive impairment in AD transgenic mice 
can be linked to the extent of synaptic mitochondrial 
dysfunction and mitochondrial Aβ peptide levels, 
suggesting that a mitochondrial signaling cascade 
induced by Aβ may contribute to cognitive impairment 
(111). Further, chronic sleep deprivation caused 
mitochondrial dysfunction in the frontal cortex of mice 
and a significant mitochondria-related Aβ increase 
in this cortical region suggesting that chronic sleep 
deprivation-induced mitochondrial dysfunction 
might be related to frontal mitochondria-related Aβ 
accumulation, preceding Aβ deposition in any other 
frontal cortical regions (112). These findings and the 
strong link of sleep-disruption in AD indicate a strong 
link between AD and sleep (113). It has been shown 
that insufficient sleep facilitates the accumulation 
of Aβ (114), potentially triggering earlier cognitive 
decline and conversion to AD (115). The sleep-wake 
cycle influences brain Aβ levels, and sleep deprivation 
increases the concentration of soluble Aβ leading to 
its accumulation, whereas sleep extension has the 
opposite effect (116). Furthermore, Aβ accumulation 
leads to increased wakefulness. Individuals with still 
normal cognitive functions and early Aβ deposition, 
report sleep abnormalities, similarly to mild dementia 
patients with incipient AD. Thus, sleep deprivation and 
AD may mutually amplify each other (117–118).
FMRI results suggest that the mechanism 
of the decline in short-term memory observed after 
acute sleep restriction is linked to the disruption of 
hippocampal-cortical connectivity (119). Age-related 
medial prefrontal cortex grey matter atrophy was 
associated with reduced non-REM SWA in older 
adults, correlating with the degree of the impairment 
of sleep-dependent memory retention. This 
memory impairment was associated with persistent 
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hippocampal activation and reduced task-related 
hippocampal-prefrontal cortex functional connectivity, 
potentially causing compromised hippocampal-
neocortical memory consolidation. Thus it seems 
that the age-related medial prefrontal cortex atrophy 
diminishes SWA, resulting in impaired long-term 
memory (120). In a human and monkey neocortical 
microelectrode array study, the state of SWS was 
associated with the highest coherence values in beta 
and gamma bands across the width of the neocortex, 
supporting the idea of the SWS-related memory 
consolidation (121). Aβ-burden in the medial prefrontal 
cortex correlates with the impairment in non-REM 
SWA generation, which in turn is associated with sleep 
memory consolidation deficits during hippocampal-
neocortical memory transfer. The association of the 
medial prefrontal cortex Aβ pathology with a deficit in 
hippocampus-dependent memory consolidation was 
indirect as it depended on the intermediary factor of 
decreased non-REM SWA. These findings suggest 
that amyloid deposition could compromise the sleep-
dependent memory consolidation via the disruption of 
the SWS (120).
In summary, changes in macrostructural 
parameters of sleep EEG indicate that alterations in sleep 
are prominent and early features of AD. However, further 
studies are required to examine the microstructural 
features including the sleep spindles, K-complexes, 
cyclic alternating patterns and high frequency oscillations. 
These microstructural features might reveal novel 
aspects of AD-related memory impairment and open new 
ways to understand how amyloid and tau could lead to 
cognitive decline (Figure 1).
3.4. Event related potential (ERP) studies in AD
ERPs are electrical potential generated by 
the brain time-locked to a sensory, cognitive, or motor 
event (123124) and originate from summed excitatory 
and inhibitory postsynaptic potentials (EPSPs and 
IPSPs, respectively) produced by synchronous firing 
of a large number of cortical pyramidal neurons with 
similar spatial orientation (125). The ERP technique 
usually involves averaging brain responses over 
a large number of experimental trials to increase 
signal-to-noise ratio. The resulting waveforms are 
informative about the time course of sensory and 
cognitive processes with high temporal resolution and 
provide coarse spatial information about the location 
of the generating structures. ERPs allow us to study 
neural correlates of information processing including 
sensory-motor and perceptual processes as well as 
higher cognitive operations such as decision making. 
Furthermore, ERPs provide safe, noninvasive, easily 
accessible and cost-effective (126) readouts of 
synaptic neurotransmission which potentially make 
ERPs an ideal tool to assess cognitive processes in 
AD. In contrast to neuropsychological tests ERPs are 
not influenced heavily by cultural background and 
educational level (127). As discussed above, there 
is a consensus in the field about AD being primary 
a disorder of synaptic plasticity (128).Given that 
ERPs are generated mainly by summated EPSPs 
and IPSPs, they may provide an ideal tool to probe 
synaptic dysfunction (129). In this section, we present 
an overview of the major ERP components and their 
relevance in Alzheimer type dementia.
Early ERPs (P50, N100 and P200) peaking 
roughly within two hundred milliseconds after stimulus 
onset are considered exogenous sensory components 
representing sensory processes as they depend 
mainly on the physical parameters of the stimulus, 
nevertheless they have been associated with attention 
as well (130). Although the prevailing view is that 
early ERP components are mostly unaffected, and 
therefore they are not ideal biomarkers in AD (131), 
a genetic study by Golob et al. showed significantly 
longer latencies for the N100, P200 components 
among familial AD (FAD) mutation carriers (132). 
Moreover reduced N100 amplitude was found in 
patients with sporadic or familial AD (133–135) and 
other abnormalities, including delayed latency of the 
P200 component have also been reported (136–137) 
indicating that early sensory-cognitive processes 
might be compromised in AD.
The N170 is a visual ERP component that 
is widely used in face perception research (e.g. 138). 
N170 amplitude is generally reported to be larger and 
more right-lateralized in response to faces than to 
other objects (139). A decrease in N170 amplitude has 
been reported in patients with AD (140–141). Although 
in a recent study Schefter et al. found no differences 
in N170 amplitude between neurotypical controls 
and aMCI patients, they have found a delayed N170 
latency in the MCI group (142) which is in line with 
compromised face processing in AD (143).
The N200 is a scalp negative waveform, 
which is evoked approximately 200ms after stimulus 
presentation. N200 is elicited by a novel infrequent 
stimulus during an oddball paradigm (usually 
investigated together with P300 component), and 
generated in fronto-central cortical areas (144). N200 is 
the earliest ERP that differentiates between target and 
non-target events, and it behaves functionally similar 
as the P300 wave. The N200 component is thought 
to represent automatic cognitive processes, such as 
pre-attentive stimulus evaluation and discrimination 
and is affected by stimulus probability. The N200 
is sometimes further partitioned into three distinct 
subcomponents: the N2a, N2b, and N2c waves. The 
N2a is often referred to as mismatch negativity (MMN) 
component which we further discuss in the next 
section. In general, the N200 is sensitive to normal 
aging, as decreased amplitude and prolonged latency 
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is observed with age (145). Although it has been less 
extensively studied in AD, a few prior studies (usually 
investigating P300 and N200 component together) 
have found delayed N200 latency in AD patients 
compared to healthy aging (127, 137). Moreover 
Howe et al. in a recently published meta-analysis of 16 
studies also demonstrated severe prolongation of the 
N200 latency in patients with AD and MCI compared to 
normative aging (126). This alteration seems to appear 
in the early course of the disease, suggesting that N200 
latency changes could reliably predict MC/early ADI, 
and the conversion from MCI to AD. The predictive 
value of N200 latency delay has been improved by its 
combination with other biomarkers, such as amyloid-b 
42 or CSF cytochrome c and also by a novel N2-P3 
inter-peak index reported by Papagliakas et al. that 
incorporates alterations in N200 and P300 latencies 
and amplitudes into a single parameter (146–147). 
Latency changes in AD have been associated with 
deterioration in attention processing and short-term 
memory processing, stimulus evaluation, and also in 
stimulus discrimination (123, 148). Furthermore N200 
amplitude was found to be more sensitive in the early 
stages of AD, than P300 latency (147). In addition, 
prolonged latency was also found among FAD mutation 
carriers (132) and according to Vaitkevicius and 
colleagues the N200 subcomponent is less influenced 
by cholinergic treatment compared to the P300 
component, therefore it may reflect the progression 
of AD more independently from cognitive-behavioral 
effects produced by cholinesterase inhibitors (ChEIs) 
(149). To conclude, alterations in latency of the N200 
component might be sensitive enough to differentiate 
patients with MCI and early AD from healthy controls 
as well as to predict conversion from MCI to AD 
(126,147). Nevertheless, more research is required 
with larger samples to determine reference values for 
N200 latency and amplitude for the differentiation of 
AD and MCI.
The P300 component has the longest history 
in clinical applications and it is the most extensively 
used potential to study dementia and aging. It is an 
objective index of cognitive activities, and in particular 
memory and context updating processes. The P300 
is a relatively large (10–20 μV), scalp-positive ERP 
component that peaks around 250ms to 500 ms) 
elicited by auditory, visual, or somatosensory stimuli 
(150). The P300 is most often investigated using the 
so-called “oddball” paradigm where a train of frequent 
irrelevant (standard/nontarget) stimuli is interspersed 
with random infrequent task-relevant (target) stimuli 
that have to be detected, and with infrequent task-
irrelevant distracter stimuli (novelty) (151). The two rare 
stimulus types elicit two different ERP components; 
the slightly earlier positive deflection called P3a is 
elicited by the distracter (task-irrelevant) stimulus 
followed by the later P3b subcomponent elicited by 
Figure 1. The multiple vicious circles of sleep loss and cognitive decline. Amyloid accumulation is the earliest and most prominent pathological hallmark 
of AD. Amyloid-induced synaptic transmission changes are well known from human and animal studies as well (6). Therefore, amyloid deposition is 
associated with altered sleep macro- and microstructure as well (122). The presence of amyloid seems to have a direct effect on sleep regulation leading 
to changes in the general sleep macrostructure (fragmented and superficial sleep, loss of slow-wave sleep) (99–101). Microstructural changes have been 
demonstrated as well (106) including decreased sleep delta power and diminished sleep spindles and K-complexes. Since these elements are essential 
for memory consolidation (108), cognitive functions are thought to be compromised directly by altered sleep and indirectly through to the impaired amyloid 
clearance mechanisms (122). There might be a bidirectional link between amyloid deposition and sleep fragmentation; impaired sleep might lead to 
increased amyloid burden (114–116), while amyloid accumulation compromises sleep regulation leading to altered macro- and microstructure (117–118).
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the target (task-relevant) stimulus (152). The P3a has 
frontocentral scalp topography whereas the distribution 
of P3b is maximum over midline centroparietal 
electrode sites (153).Target-related responses are 
thought to be generated in the parietal cortex and the 
cingulate whereas novelty-related responses in the 
inferior parietal and prefrontal regions (154), which 
also reflects interactions between the frontal lobe and 
the hippocampus (152). Regarding neurotransmitter 
systems, P3a shows strong association to the frontal/
dopaminergic circuits whereas P3b is linked to 
the parietal/norepinephrine pathways (152). P300 
originates from a distributed network associated 
with attention and working memory processes. It is 
generally assumed that the P300 component reflects 
the completed encoding of stimulus information into 
working memory (155). The P3a (involved in automatic 
novelty detection) has been linked to attentional 
processes and presumed to be an electrophysiological 
correlate of the orientation, whereas the P3b 
(associated with voluntary target detection) appears to 
be related to working memory and context updating 
processes (156). P300 amplitude increases with lower 
probability and higher discriminability of targets, and 
it is influenced by stimulus probability and saliency as 
well as availability of attentional resources (157). P300 
amplitude correlates with memory performance, in the 
cognitively unaffected biological children of AD patients 
smaller amplitudes are related to decreased brain 
activation and lower scores in cognitive tests (158). 
P300 latency generally increases with the complexity 
of the stimulus evaluation and decision processes 
demanded by the task and indicates the closure 
of stimulus processing (152) as well as response 
selection (159). It appears to be also correlated with the 
agility of mental functions, thus a lower P300 latency 
is associated with superior cognitive performance 
(160) and reaction times (161). P300 is relatively 
independent of physical characteristics of the sensory 
input (157). Furthermore, the amplitude, latency and 
scalp topography of the P300 are modulated by a 
variety of factors that also tend to influence cognition, 
such as age (162), learning (163), substance use 
(164), pharmacological interventions (165), exercise 
(150) and diseases, particularly mental illnesses 
(166). P300 is sensitive to normal aging, as its latency 
increases in a linear fashion with 1 to 2 msec/y (167). 
Its topography tends to shift frontally with age (161) 
and its amplitude is progressively decreasing (168).
In general, several previous studies 
consistently reported a prolonged P300 latency in AD 
patients compared to age-matched healthy controls 
(for review see 169). P300 latency has been highly 
correlated with the severity of cognitive deficits in AD. 
Its latency increases as cognitive abilities decrease 
(170); in particular it was found to be sensitive to 
deterioration of language, memory, and executive 
functions (171). Although the majority of P300 studies 
in AD focused on its latency, changes in its amplitude 
have also been found (172). A meta-analysis and 
meta-regression by Hedges et al. in concluded that the 
amplitude of the P300 component after an auditory or 
visual oddball stimulus was also significantly lower in 
probable Alzheimer’s disease than in healthy controls 
(173). Moreover several recently published studies 
showed sensitivity and specificity above 80% (174). 
Studies that have differentiated between P3a and P3b 
latencies, reported more prolonged P3a latency in AD 
(126, 174). Also prolonged P300 latency has been 
reported in patients with MCI compared to healthy 
controls, and shortened P300 latency when compared 
to patients with AD. Two recent meta-analyses of these 
findings reported strong evidence that P300 latency 
can reliably differentiate between groups of MCI 
patients and controls (126, 175). Moreover Jiang et al. 
showed shorter P300 latency and larger amplitude in 
stable MCI patients compared to AD converters, and 
they suggested that P300 measures can predict MCI 
progression to AD (175). Furthermore, delayed P300 
latency has been associated to positive cognitive 
response during cholinesterase inhibitor (ChEI) 
administration (131, 149). P300 latency has followed 
the same dynamics as the cognitive functions: initial 
improvement after 3 months of treatment, plateau 
phase of several months, and the gradual decrease 
after 6–12 months and later (150).The pre- and post-
treatment latency differences were also correlated with 
cognitive ability and memory performance (131, 170, 
176–177). Increased P300 amplitudes were found 
among normal subjects with first degree relatives of 
autopsy confirmed AD cases (178). An association has 
been revealed with genetic mutations, P300 latency of 
subjects carrying the apolipoprotein E (APOE) 4 allele 
(E4+) and with a positive family history of AD has been 
significantly longer than those of negative family history 
(155, 173–179). Furthermore, familial AD mutation 
carriers had significantly longer P300 latencies, 
which, together with other ERP abnormalities appear 
approximately 10 years before dementia manifestation 
(132). P300 changes have been shown to be positively 
correlated with neuropsychological test scores used 
in AD, such as the Trail Making Test Part B (TMT-B), 
the Wechsler Memory Scale, and digit span test that 
assess executive and working memory functioning. 
Furthermore Lai et al. suggested that P300 latency 
might be even a more sensitive index of cognitive 
decline than neuropsychological testing according to 
a longitudinal follow-up study in AD (170). Regarding 
variations in oddball protocols, a recent review of 
P300 studies in AD concluded that while the P300 
assessment methodology is consistent across studies, 
the intensity, duration and type of stimuli, as well as the 
inter-stimulus interval and also the target-related task 
vary substantially among the studies (169).
In summary, P300 is associated with memory 
and cognition which are impaired in AD, which is in line 
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with the fact that presumed generator sites (centro-
parietal cortex, frontal cortex, and hippocampus) are 
usually also affected in AD.P300 latency and also 
amplitude abnormalities have been suggested as 
sensitive tools to detect cognitive decline in patients 
with AD. P300 changes appeared to be objective 
and sensitive measures for discriminating subjects 
with MCI from controls and AD patients; moreover 
changes in P300 might be useful in the detection of 
the transition from MCI to AD. Furthermore, genetic 
studies found P300 abnormalities even in preclinical 
AD while subjects are in an asymptomatic stage. 
Pharmacological studies indicate the P300 latency 
could also be useful in quantifying the effect of 
the central nervous system’s (CNS) response to 
medication.
Deviations in congruency expectations about 
meaningful stimuli such as words elicit the N400 event 
related potential which has been widely used as an 
index of lexical and semantic processing (180). Deficits 
in language and sematic integrative processes are 
known to be characteristics of AD (181),therefore the 
N400 might be a promising candidate to study this type 
of dementia.N400 is a negative-going potential peaking 
between about 250–550 ms) with maximal distribution 
over the centro-parietal electrode sites, although 
distribution can vary across protocols depending on 
the nature of the eliciting stimulus. Its amplitude can 
range from -5 to 5 µV (182). Studies using invasive 
electrophysiology and magnetoencephalography 
localized N400 generators in the temporal, parietal 
and the prefrontal cortical regions (180, 183). The 
N400 N400 effect is usually calculated by contrasting 
responses to congruent and incongruent stimuli to 
reveal the ERP component related the investigated 
experimental variable (182).
Sematic priming and repetition priming have 
been used widely to examine semantic memory 
functions in AD (175). Semantic priming (SP) 
facilitates retrieval of target words that are preceded 
by contextually related priming words compared 
to words in unrelated context (184). The N400 is 
sensitive to semantic congruity, and its amplitude is 
positively correlated with semantic processing load 
and negatively correlated with semantic expectancy. 
Thus semantically incongruous (inappropriate or 
unexpected) stimuli elicit larger responses compared 
congruous stimuli (185), frequently described as N400 
effect. As it is generally assumed, N400 SP effect 
represents a more prominent signal processing need 
on neural resources for unexpected stimuli relative 
to the expected ones (182). Other repetition priming 
effects are reviewed later in the P600 section.
The N400 component as well as the N400 
SP effect was found to be smaller and delayed in the 
elderly (186) indicating that the N400 is affected in 
normal aging. Nevertheless, the majority of studies 
investigating N400 effects based on manipulations of 
semantic congruity in AD consistently revealed reduced 
N400 amplitudes or slower latencies compared to 
elderly controls (187). Moreover, different topographic 
N400 congruity effects have been shown in AD patients 
(188). Reduced N400 semantic congruity effect in AD 
patients relative to controls was found to sentence-
terminal words of visual (189) or auditory (190) 
sentences, to visual words congruous/incongruous to 
the preceding category (191), to semantically related/
unrelated line drawings and pictures (192), as well 
as to picture primes followed by visual word targets 
(193) or to visual words followed by picture targets 
(188). In contrast to the aforementioned findings, 
other studies reported normal N400 congruity effect 
in mild AD suggesting a relatively preserved semantic 
memory (189). However, in a recent study using an 
ERP paradigm optimized for AD corroborated the 
aforementioned positive results and found decreased 
N400 amplitudes among MCI/early AD patients 
compared to normal controls (76, 135). Furthermore 
studies investigating the word-repetition effect also 
showed significant attenuation of the N400 effect 
and an additional atypical anterior N400 distribution 
in patients with AD compared with controls (135). 
Nevertheless, the authors observed a typically shaped 
N400; hence they suggested preserved semantic 
knowledge but impaired access in AD (Word repetition 
effect is further discussed in the P600 section.) MCI 
patients also tend to show delayed N400 latencies, 
reduced N400 semantic congruity and word repetition 
effect compared to healthy elderly subjects (194). 
Olichney et al. have shown in a longitudinal study that 
MCI converters had abnormal N400 effects (loss of both 
the N400 repetition effect and N400 congruity effect), 
which were present at year 1, and became pronounced 
by year 2. Moreover an abnormal N400 (or P600) effect 
was associated with an increased risk of transition 
from MCI to AD. They also found an atypically anterior 
N400 distribution in MCI converters, similar to mild 
AD (129). Abnormal N400 topography was found by 
Grieder et al. to be associated with decreased anterior 
temporal cerebral blood flow (possibly reflecting the 
underlying pathology), and they suggested that N400-
topography alterations might be a potential biomarker 
for the detection of early dementia (195). Furthermore, 
according to Bobes et al., deviant N400 topographies 
might occur even before the manifestation of 
semantic memory symptoms. They reported abnormal 
parietal distribution of N400 congruity effect among 
asymptomatic carriers of E280A PS-1mutation (196).
In sum, altered N400 semantic congruity 
effect in AD likely reflects the well-known dysfunction 
of semantic memory processes in AD (181). 
Abnormalities of N400 (reduced N400 effect and 
altered topography) have been consistently found in 
previously published studies of mild AD and MCI and 
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they seem to be related to the anterior temporal lobe, 
a predilection site for AD pathology (38). Abnormalities 
of the N400 effect (including both semantic congruity 
and word repetition effect) may offer sensitive markers 
for detecting and monitoring the stages of disease 
progression in very early AD and for the subsequent 
transition from MCI to AD. Moreover deficits of N400 
effects in cognitively normal elderly persons may be an 
important sign of preclinical AD.
The P600 or Late Positive Component (LPC) 
has been suggested as an index of memory encoding 
and retrieval processes, including episodic and 
declarative memory (129). The P600 component is a 
large late positive waveform, with a centro-posterior 
distribution, which reaches its peak around 600 
milliseconds after stimulus presentation. Intracranial 
studies concluded that putative P600 generators 
include several paralimbic cortical regions (cingulate, 
orbito-frontal cortex and temporal pole), the medial 
temporal lobe (MTL) including the hippocampus and 
entorhinal cortex, and further multi-modal association 
neocortical regions (ventrolateral prefrontal, lateral 
temporal cortex). Depth recordings in several 
paralimbic and association neocortical regions have 
shown biphasic ERP components which resemble 
the N400–P600, suggesting a link between these 
components (197). Studies in dementia focusing on 
the P600 have mainly used repetition priming to probe 
memory processes.
Behavioral effects of repetition priming 
typically include improvements in response speed 
or accuracy to repeatedly presented stimuli (198). 
Both the N400 and P600 can be reliably elicited and 
modulated using a word repetition paradigm. In word 
list recognition experiments recognized/remembered 
words that go through a more extensive encoding 
process evoke larger late positivity (199). In contrast, 
preceding semantic contexts which increase the 
probability of a word’s repeated occurrence have the 
opposite effect (200). While diminished N400 repetition 
effects have been linked with abnormal semantic/
conceptual priming (201), P600 priming effects have 
been associated with episodic verbal memory and 
declarative memory skills (192).
Prior studies of ERP word repetition effects 
in AD have reported inconclusive results (202–204). 
However, Olinchey et al. used a semantic categorization 
task in a word repetition paradigm that manipulated 
semantic congruity and repetition. ERPs obtained in 
their paradigm showed high sensitivity and specificity 
(100% and 80%, respectively) to AD. They consistently 
have found reduced or absent P600 and N400 word 
repetition effects as well as atypical anterior N400 
distribution in patients with AD compared to controls 
(135, 200). Using the same word repetition paradigm in 
an fMRI study they have found left hemisphere dominant 
repetition effects in medial temporal, prefrontal and 
parietal networks associated with both encoding and 
retrieval of episodic memory (205).
The aforementioned research group has also 
demonstrated reduced P600 word repetition effects 
in patients with MCI (195). Furthermore, reductions 
in either the P600 or N400 word repetition effect in 
MCI patients were associated with greater likelihood 
for conversion to AD dementia (129). Olinchey and 
colleges used an incidental verbal learning paradigm 
with high sensitivity to prodromal AD in seven elderly 
subjects, who had normal cognition at the time of 
ERP recordings but showed subsequent cognitive 
deterioration or had AD pathology confirmed by 
autopsy. A reduced P600 repetition effect was found 
compared to normal elderly controls. The P600 effect 
was severally compromised even in patients with 
minimal neurofibrillary pathology, and the authors 
suggested that amyloid deposits might disrupt effective 
communication within the network of neural generators 
underlying the P600 response (206).
In conclusion, progressive alteration of the 
P600 effect may be a manifestation of failing P600 
generators, which may relate to the early involvement 
of the medial temporal lobe. The MTL (anterior 
fusiform, parahippocampal gyrus, hippocampus) 
is known to be involved in the early neuropathology 
of AD; deficits in the episodic memory are usually 
the earliest symptoms. ERP word repetition effects 
appear to be very sensitive to AD and MCI. P600 and 
N400 repetition effects have consistently been found 
diminished in AD which may be linked to semantic 
and memory impairments. Decreased P600 and N400 
repetition effects appear to be useful biomarkers for 
predicting conversion from MCI to AD dementia, thus 
altered P600 effects in elderly with normal cognition 
could be a red flag for preclinical AD.
The emerging picture after overviewing the 
abnormalities of cognitive ERPs in AD shows that early, 
sensory-evoked potentials are usually found to be less 
affected in AD, although the results are not entirely 
conclusive. Later potentials reflecting higher cognitive 
processes, such as the P300 component, could be 
more effective for detecting the progression of cognitive 
decline and attention deficits, thus it could prove to 
be a useful biomarker in CNS drug development. A 
decreased P600 and N400 repetition effect and also 
a delayed N200 latency can be detected consistently 
in the early stage of the disease therefore they could 
reliably predict the conversion from MCI to AD. 
Interestingly, genetic and longitudinal studies also found 
the abnormalities of several ERP components (N200, 
P300, N400, and P600) in the pre-symptomatic stage of 
AD. ERP abnormalities are not specific to Alzheimer’s 
disease; they have been also documented in several 
other neuro-psychiatric disorders. The sensitivity 
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and specificity of ERP measurements showed great 
variability in the literature; therefore the diagnostic validity 
of these measurements seemed to be poor. However, 
recently several studies using promising clinical ERP 
approaches presented prediction accuracies of MCI/
AD progression in the 85–95% range (129, 207–208).
The separation of subcomponents (174) and also the 
additional use of two or more components of the event-
related potentials (147, 208), the combination of ERP 
measurements with event-related synchronization 
(ERS) measurements (136) or with neuropsychological 
tests has been found to be useful to increase sensitivity 
and specificity (165) and thus improve reliability of the 
overall test procedure. Furthermore the importance of 
the use of carefully designed paradigms with higher 
sensitivity to AD (137, 199), MCI (194) or even to 
prodromal AD (206) has been highlighted (Table 3).
3.5. Mismatch-negativity (MMN) studies in  
AD and MCI
The mismatch negativity (MMN) is an ERP 
component generated automatically in response to 
events that deviate from what is likely to happen. A 
commonly used experimental protocol to elicit MMN is 
the oddball paradigm (209), where frequent, standard 
stimuli are interspersed with rare, deviant stimuli. The 
MMN component is usually obtained by subtracting 
the ERPs to standards from those to deviant stimuli. 
Although MMN can be elicited by stimuli in virtually 
all sensory modalities, auditory and visual paradigms 
have been used most frequently. Automatically 
detecting a change in the sensory input works not only 
at the level of simple acoustic or visual features, but 
also at higher, more abstract stimulus attributes (209). 
The MMN has been proposed to reflect the automatic 
functioning of a “primitive intelligence” (210), which 
generate predictions about future events by extracting 
invariant patterns from the varying environmental 
sensory input even when they are task-irrelevant. 
Extracting such regularities (211) in the absence of 
attention corresponds to implicitly keeping track of 
statistical probabilities of sensory events (212) that 
allows detecting improbable events; the mismatch 
between predicted and observed stimuli is thought to be 
signaled by the MMN response, thus it is increasingly 
considered as a perceptual prediction error signal 
(203–219). Since such signals play a fundamental 
role in veridical sensory and cognitive processes, the 
MMN component is a suitable candidate as a marker 
of cognitive decline.
3.5.1. MMN in AD
According to the guideline for the diagnosis 
and management of Alzheimer’s disease by the 
European Federation of the Neurological Societies 
(EFNS), spectral EEG markers based on oscillatory 
power alterations in different frequency bands may 
help to differentiate between AD, subjective complains 
and psychiatric diagnoses (220). However, ERPs are 
currently not listed in the guideline. ERPs or MMN in 
particular, to qualify as a clinical marker, should have 
a sufficiently high sensitivity for detecting early AD, as 
well as a sufficiently high specificity for distinguishing it 
from other neurodegenerative disorders. Furthermore, 
according to the Consensus Report of the Working 
Group on Molecular and Biochemical Markers of AD 
(221) by the Ronald and Nancy Reagan Research 
Institute, an ideal marker should be non-invasive, 
simple to perform, and inexpensive. However, currently 
only diagnostic approaches based on cerebrospinal 
fluid-tau and positron emission tomography (PET) 
approaches demonstrated sensitivity as well as 
specificity in the range of about 70%-100% (222). 
Clearly, markers obtained with these methods do not 
fulfill the above ideal requirements of non-invasiveness 
and cost-effectiveness. Regarding biomarkers 
for disease progression, a recent systematic 
review by McGhee et al. (223) found that the most 
commonly studied marker was brain MRI, whereas 
electrophysiological studies made up only a small 
fraction of the included studies. They found that studies 
were generally of poor quality, underpowered due to 
relatively small number of participants, and had flawed 
methodologies, indicating that the field in general 
 Table 3. Changes in amplitude and latency of different ERP components in AD, MCI and preclinical stages
of AD
ERP component Amplitude in AD Latency in AD Amplitude in MCI Amplitude in preclinical AD Effect of cholinergic treatment
Early ERPs IC IC DNA DNA DNA
N170 ↓ / IC ↑ DNA DNA DNA
N200 ↓ ↑↑ ↑ ↑ Less influenced by cholinergic 
treatment
P300 ↓↓↓ ↑↑↑ ↑↑↑ ↑↑ Response to cholinergic treatment
N400 ↓↓ ↑↑ ↑↑ ↑ DNA
P600 ↓↓ ↑↑ ↑↑ ↑ DNA
The number of arrows indicates the number of studies reporting concordant results: ↑ = 1–5 studies ↑↑ = 5–10 studies ↑↑↑ >10 studies. DNA = Data not 
available; IC = inconclusive results.
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needs to adopt stricter methodological guidelines. The 
authors concluded that there was insufficient evidence 
to recommend any biomarker as an outcome measure 
for disease progression in Alzheimer’s disease (223) 
and recommended a “roadmap” for future studies.
Earlier reviews on electrophysiological 
biomarkers, including MMN, were optimistic and 
suggested that ERP components may serve as clinically 
useful, objective, noninvasive, economic and reliable 
method for assessing neurological disorders, including 
AD (130, 224). The first auditory MMN study (225) that 
used duration deviants in AD patients (n=9) reported 
that MMN amplitude decreased more in the patients 
than in the age-matched controls, and suggested that 
the memory trace reflected by the MMN response 
decays faster in the AD patients. In a subsequent 
magnetoencephalography (MEG) study by Pekkonen 
et al. (226) that used a similar oddball paradigm, 
AD patients (n=22) had significantly delayed N100m 
responses in the left hemisphere that correlated with 
the impairment of language functions. Unfortunately 
MMN was not investigated due to constraints on the 
recording time in the study. Kazmerski et al. (227) 
used both an active and a passive oddball paradigm 
in probable AD patients (n=16), age-matched and 
young controls. They found a decreased MMN both 
in AD patients and older controls during both active 
and passive oddball paradigms, although reliably 
MMN amplitude differences were observed primarily 
during the active oddball sequences. In general, the 
AD group showed reduced MMN amplitudes relative 
to the older controls, although these differences were 
not always statistically reliable. Gaeta et al. (228) 
systematically varied stimulus deviance to study 
whether the mechanism underlying the MMN can 
track wide differences in the physical characteristics 
of auditory stimuli. They found that patients with mild 
AD (n=8) showed robust MMN responses to the three 
types of deviant stimuli which did not differ in amplitude 
or latency from that of the old control group, and 
suggested that patients with mild AD have an intact 
sensory memory mechanism.
The robust effect of ageing on MMN has been 
shown in several studies in the auditory (229–230), 
visual (231–232), and somatosensory (233) modalities. 
A recent meta-analysis on the effects of physiological 
aging on MMN (234) concluded that an attenuated 
MMN to duration and frequency changes is a robust 
feature in healthy aged adults. Thus, the MMN, as a 
potential biomarker in AD, should be specific enough 
for differentiating the baseline effect of healthy aging 
from a putative AD-specific alteration of the MMN.
3.5.2. MMN in MCI
The transitional continuum between normal 
aging and dementia is referred to as MCI. There is a 
considerable clinical and pathological heterogeneity 
in MCI (235), which precludes reliably predicting 
transition to AD (236). Furthermore, pathological 
studies (237) confirmed remarkable heterogeneity of 
AD subtypes and progression rates. Nevertheless, 
there is complex but predictable relationship between 
the severity of cortical pathology and the extent of 
cognitive impairment (238). At-risk individuals with 
MCI would particularly benefit from a biomarker at 
this early stage of AD as it would allow early detection 
before irreversible degeneration takes place and 
prevent progression to full AD. Indeed, differentiating 
between MCI, AD, and physiological ageing, as 
well as other forms of dementia is a central issue in 
more recent MMN studies. Mowszowski et al. (239) 
investigated auditory MMN and its relationship to 
neuropsychological performance in MCI individuals 
(n=28) and age-matched controls. Looking at MMN 
at temporal sites they found reduced responses in the 
MCI group. The reduced MMN at the right temporal 
site showed a relationship with poorer verbal learning, 
whereas reduced MMN at left temporal site was 
associated with increased disability. The authors 
suggested MMN may be a viable neurophysiological 
biomarker in the at-risk MCI group, however they failed 
to correct for multiple comparisons in their correlation 
statistics. A recent longitudinal study (240) used 
auditory MMN in a cohort of MCI individuals. At the 
first time point n=26, at the follow-up n=7 MCI patients 
were included in the analysis. The two evaluations 
were separated by an interval of 1.5–2 years. At the 
first time point, significant group differences were 
observed only in the 50–64 years age range, but not 
in the >65 years range. At the second time point only 
one age range (62–89 years) was studied. The MMN 
amplitude was reduced in the MCI compared to the 
control group in both evaluations, although significant 
group differences were not present between MCI and 
control adults in the >65 years range.
Ji et al. (241) used auditory MMN to 
compare automatic change detection in amnestic MCI 
individuals (n=43) and age-matched controls. Both 
MMN amplitude and latency were analyzed. Results 
showed that while amplitudes did not differ between 
the two groups, the latency of the MMN component 
was significantly delayed in the aMCI adults. Although 
no other clinical test groups were included in the study, 
the authors concluded that MMN latency appeared to 
be a sensitive and specific biomarker of MCI. A high-
density EEG-3D vector field tomography approach was 
used by Papadaniil et al. (242) to investigate auditory 
MMN in MCI (n=21) and AD patients (n=21) as well as 
healthy elderly controls at the scalp and at the source 
level. Analysis of MMN amplitude and latency at the 
scalp showed significantly delayed response in the 
AD group compared to the healthy elderly. Source 
reconstruction revealed curiously similar activation 
patterns for the MMN and the P300 component. Several 
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MMN-related activations were found to be significantly 
different across the groups; however statistical tests 
were not corrected for multiple comparisons, making 
interpretation of the results difficult. The authors 
concluded that alterations of MMN might serve to create 
biomarkers of dementia and its progression. Three 
groups of subjects were investigated by Idrizbegovic et 
al. (243) using auditory MMN. Patients with AD (n=32), 
MCI (n=44), and patients with subjective memory 
complaints without cognitive decline (SMC, n=27) 
were included. Stimulus was presented monaurally, 
separately to the right and left ears. The MMN in the 
left ear condition was significantly smaller in the AD 
compared to the MCI group. Furthermore, a left ear 
advantage (LEA) of MMN was observed in the MCI 
and SMC groups, which was absent in AD group, 
however the LEA was not systematically tested across 
the groups. The authors speculatively concluded 
that the absence of MMN asymmetry in AD might be 
related to a dysfunction to register changes in tonal 
stimuli. Another study that used auditory MMN as an 
index of cognitive decline included a final sample of 
amnestic MCI (n=8) and AD patients (n=12), as well 
as age-matched controls (244). MMN was elicited 
with shorter and longer inter-trial intervals (ITI), and 
was measured at frontal and temporal sites. Results 
showed that at short ITI, in MCI and AD patients MMN 
was only found at temporal sites, whereas in healthy 
elderly it was present at both frontal and temporal 
sites. At longer ITI, MMN was absent in the patient 
groups, only healthy controls showed a reliable MMN 
response at temporal sites. Unfortunately it is not clear 
from the results whether the lack of a significant MMN 
response in the patients corresponds to a reliable 
difference in MMN between the control and any of the 
patient groups. Significant correlations were found 
between MMN amplitude and neuropsychological test 
scores; however the statistics were not corrected for 
multiple comparisons. The authors suggested that 
the auditory MMN might be adopted as a marker for 
cognitive decline in pathological ageing.
MMN in the visual modality has also been 
used to differentiate between healthy and pathological 
ageing. In a study in AD patients (n=8), age-matched 
and young adults Tales and Butler (245) found that 
while the visual MMN response had a relatively 
constant amplitude in the older controls, it was absent 
in the first experimental block and much larger in the 
second block. In a subsequent study (246) the same 
group investigated visual MMN in MCI (n=8) and AD 
(n=10) groups as well as age-matched controls. They 
found that both the MCI and AD patients showed a 
significantly increased vMMN in the 140–250 ms time 
window compared to healthy elderly. In this interval 
both the MCI and AD groups failed to show a significant 
vMMN in the first experimental block but exhibited a 
significant vMMN response in the second, showing the 
same pattern as in their previous study (245). However, 
in a recent follow-up study (247) with a larger cohort of 
AD (n=20) and MCI (n=25) patients as well as healthy 
older controls no significant difference between AD 
patients and healthy older adults was found in vMMN 
amplitude. Results showed though that MCI patient 
had a reduced vMMN response compared to elderly 
controls. However, earlier ERP components such as 
P1 was reduced in AD patients, and N1 amplitude was 
attenuated in MCI and AD patients relative to controls, 
furthermore vMMN and lower P1 amplitudes showed 
a relationship with cognitive impairment scores. The 
authors concluded that visual evoked potentials and 
MMN may provide objective markers of cognitive 
decline.
The specificity of MMN to differentiate 
between neurodegenerative disorders has been 
tested in two studies. Brønnick et al. (248) compared 
auditory MMN responses in patients with dementia 
associated with Parkinson’s disease (PDD, n=15), 
dementia with Lewy-bodies (DLB, n=17), AD (n=16), 
Parkinson’s disease without dementia (PD, n=16) and 
healthy control subjects. Results showed that PDD 
patients had reduced MMN compared to the DLB, PD, 
and the HC groups, but did not differ significantly from 
the AD group. Another recent study (249) compared 
auditory MMN in patients with AD (n=15), bipolar 
disorder (n=25), schizophrenia (n=49), and healthy 
controls. Significant reduction in MMN amplitude was 
only observed in the schizophrenia group. Despite the 
relatively larger cognitive deficit in the AD group, the 
MMN findings showed intact sensory and cognitive 
processes.
3.5.3. Conclusions
The overwhelming majority of the studies 
reviewed here reported some MMN alterations in 
MCI and/or AD patients. However, different studies 
observed different alterations either in latency or 
amplitude, or at different scalp locations. Outcome 
variability is a serious issue which may relate to 
several factors. First, the small sample size in many 
studies renders their statistics underpowered. Effect 
size was often not communicated in the results, which 
makes comparisons between studies difficult. Larger 
samples would possibly allow to handle the issue of 
disease heterogeneity, i.e., by the identification of 
more consistent subgroups within the heterogeneous 
disease population. Second, studies differ to a large 
extent in their stimulation protocols, measurement 
parameters, and data analysis. Furthermore, some 
studies had presumably flawed methodologies, and 
apparently several studies had flawed statistical 
analyses. Other factors that might contribute to the 
outcome variability include the medication status 
of the participants which is very often ignored, 
together with other potentially useful covariates (e.g., 
cognitive reserve, demographics). Furthermore, the 
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overwhelming majority of the studies were cross-
sectional, which has precluded later verification of the 
MCI status at the time of the study.
With regard to the issue of sample size, future 
studies would benefit from performing a power analysis 
to determine the required sample size to optimize the 
probability of detecting a true effect given a desired 
effect size. Regarding disease heterogeneity, the 
lack of longitudinal studies in the field clearly hinders 
the accurate evaluation of any MMN-based markers 
due to limited predictive accuracy of the MCI label. 
Furthermore, machine learning techniques that have 
been used on MRI data to discriminate subgroups in 
MCI patients (250) might be useful to define subgroups 
in the heterogeneous at-risk and disease populations. 
An optimal experimental protocol could be adopted 
to overcome excessive variation in measurement 
parameters and analysis across studies.
3.5.4. Future directions – Computational  
neurology
The majority of the studies reviewed here 
observed a change in the amplitude or latency of 
the MMN in MCI and AD patients. However, the 
sensitivity and specificity of these alterations in simple 
characteristics of the MMN response, such as amplitude 
or latency, are unlikely to be sufficient to qualify MMN 
as a biomarker in the early diagnosis of, or outcome 
predictor in AD (251). However, recent advances in 
computational neuroscience provide us with tools to 
investigate the population dynamics of the neuronal 
networks underlying ERPs. Dynamic causal modeling 
(DCM) studies revealed the dynamics of the functional 
network underlying the MMN component (213–214, 
252). The development of computational tools that 
allow studying large-scale neuronal population 
dynamics has led to the emergence of a new field at 
the interface between neuroscience and psychiatry 
that aims to use computational methods to identify 
objective diagnostic assays, and to overcome issues 
arising from the enormous heterogeneity in spectrum 
diseases that are traditionally diagnosed according to 
subjective symptoms (253–254). The new discipline 
of computational psychiatry uses neurobiologically 
motivated formal models that describe brain function 
in computational or mathematical terms for elucidating 
mechanisms of pathophysiology that may inform both 
diagnosis and treatment (14, 255–256). For example, 
parameter estimates of network connectivity obtained 
from dynamic causal models of the auditory MMN 
have been successfully used to differentiate between 
patient populations and controls in vegetative state 
(257) and schizophrenia (258).
DCM of the MMN response is a promising 
tool to characterize glutamatergic dysfunction in 
schizophrenia (259) and it also might prove useful to 
quantify cholinergic dysfunction in AD (260–261), as 
recently Moran et al. (262) demonstrated that DCM 
is feasible to characterize cholinergic effects on the 
MMN component, which was found to modulate gain 
in pyramidal cells in the auditory sensory cortex. 
Furthermore, recent DCM studies revealed that 
the observed attenuation of the MMN response in 
healthy ageing is likely due to alterations in forward 
connectivity within temporal (263) and/or between 
temporal and frontal regions (264). Thus, although 
an index of cognitive decline based on a simple 
amplitude measurement of the MMN is unlikely to yield 
sufficient sensitivity and specificity to qualify this ERP 
component as a biomarker, computational models 
of the MMN might allow effectively disentangling the 
factors of healthy aging and pathological alterations as 
they seem to affect the network underlying the MMN in 
different ways.
The example of MMN, one of the most studied 
cognitive brain potential, highlights that translating 
the advances in computational modeling tools of 
basic neuroscience to psychiatric and neurological 
population might allow us to tackle long-standing 
issues in these fields. By applying novel approaches 
to better understand disease mechanisms, we 
might abandon subjective symptom-based disease 
categories and dissect the currently heterogeneous 
clinical populations and spectrum disorders into 
subgroups defined instead based on alterations in 
neurobiological mechanisms. In this challenging 
mission at the interface of neuroscience and neurology 
(265), markers derived from spontaneous EEG, as 
well as sensory-cognitive brain responses such as 
MMN and other ERP components have the potential to 
contribute to the development of computational assays 
that might inform diagnosis and treatment, and track 
disease progression.
4. EEG IN THE DIFFERENTIAL DIAGNOSIS 
OF COGNITIVE DECLINE
The differential diagnosis of neurocognitive 
disorders may be difficult due to several diseases 
with overlapping clinical symptoms and the large 
inter-individual variability in the progression and 
manifestation of the disorders. Apparently the 
revolution of the neuroimaging techniques has 
significantly improved our diagnostic accuracy in 
neurodegenerative disorders. However, EEG/ERP 
methods might offer many, still unexploited benefits 
both in research and clinical areas. In this section we 
briefly overview the potentially useful EEG methods 
in the differential diagnosis of various dementia 
syndromes.
Frontotemporal dementia (FTD) that affects 
mainly the anterior temporal pole and the prefrontal 
cortex is responsible for 15% of cognitive deterioration 
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cases. In the early phase of the disease changing 
behavior and progressive speech difficulties dominate 
the clinical symptoms. Subsequent progression affects 
episodic memory functions as well. Differentiation 
from AD is frequently challenging, especially in the 
early stages, when FTD can mimic the symptoms of 
AD (266). An early study with pathologically confirmed 
FTD demonstrated that the EEG did not show 
specific changes when analyzed by visual inspection 
however a marginal elevation in theta power could 
be observed (267). Further studies also showed that 
visual inspection of the EEG demonstrated normal 
appearance compared to AD (268). In contrast, 
quantitative EEG methods revealed a significant 
decrease in spectral power of the alpha and beta band, 
while lower frequencies were unaffected (269). A recent 
global field power analysis (270) corroborated these 
prior findings. A LORETA study yielded similar results 
for the delta band but found no differences in the higher 
frequencies between FTD and AD patients (271). The 
major difference between AD and FTD seems to be 
the increased spectral power of delta and theta band in 
AD (272), while it remains unaffected in FTD according 
to most of the studies (269–271). Graph analysis 
also indicated a potentially distinctive measure; AD 
patients showed the features of random systems, 
while FTD patients presented changes towards a more 
ordered network (92). However, another study using 
a similar network analysis approach did not find any 
differences (268). PLI and MST analysis indicated that 
FTD patients present lower theta band whole-brain 
PLI and higher alpha band whole-brain PLI than AD 
patients, while MST indicated that frontal networks are 
selectively involved with a preserved global functional 
efficiency compared to AD where the global efficiency 
was significantly impaired by occipital and parietal 
network dysfunction (273). D2 complexity was also 
reduced in FTD and the increase in eyes-opened 
condition was diminished compared to normal controls 
(274), similarly to the findings in AD. While there is a 
special genetic phenotype of FTD with parkinsonism 
and epileptic seizures (275), unfortunately only one 
study is available about the prevalence of epileptic 
seizures in FTD (276). It revealed seizures in 5% of 
FTD patients (276); in contrast, epileptiform EEG is 
frequently observed in AD (277).
Mood disorders such as major depression 
and anxiety disorders are frequent comorbidities of 
neurocognitive disorders. It is still unclear, whether 
late-life depression is a risk factor of AD or a prodrome 
of the disease (278). It is also well-known that 
depressive symptoms could mimic cognitive decline, 
therefore differential diagnosis of mood disorders and 
AD is necessary, however, it is often difficult. EEG is 
a useful tool to discriminate AD patients from late-
life depression with a 70–85% reported accuracy 
(279). The major finding in depression studies is the 
elevated alpha and beta power, especially bilaterally 
in the anterior regions (280). In coherence studies, 
the most consistent finding in patients living with 
depression is the reduced frontal interhemispheric 
coherence in all frequency bands (280–281). 
EEG complexity studies showed similar results in 
depression and AD, both diseases demonstrating a 
significant loss in interhemispheric coherence (282). 
Many functional connectivity studies indicated that 
patients with depression show increased connectivity, 
in short-connections of the left hemisphere and in 
long-associations of the right hemisphere (283). 
Thus, the major features those differentiate between 
AD and depression in EEG include the increase in 
fast frequencies, the unaffected low frequencies, the 
dominance of EEG changes of the frontal lobes and 
the generally elevated connectivity in depression.
Diffuse Lewy-body dementia (DLB) and 
Parkinson-dementia (PDD) are synucleinopathies 
showing typical motor phenomena, so the 
differentiation from AD is usually straightforward. 
However, visible symptoms that usually accompany 
impairments of the motor pathways are not present 
in each patient; in these cases EEG could serve as a 
useful diagnostic tool (284). EEG studies in DLB and 
PDD reported a decrease in alpha power and diffuse 
slowing could be demonstrated in both conditions 
(285). Interestingly, loss of alpha dominance and 
slowing could be more prominent in DLB compared 
to AD (286–287). Bilateral frontal intermittent rhythmic 
activity (FIRDA) is a common feature of EEG in DLB 
(288).Grand total EEG score (GTE) was able to 
distinguish AD from DLB with 72% sensitivity and 80% 
specificity (289). Increased dimensional complexity, 
higher entropy and nonlinearity were demonstrated in 
PD, while these parameters decreased in PDD (290–
291). Stam et al. observed elevated L1 in PD patients, 
but no data regarding PDD are available (292). In 
PDD, a decrease in functional connectivity was found 
with a similar pattern as in AD (293), while studies on 
non-demented PD patients reported increased alpha 
and beta band connectivity cortical areas as well as 
between the subthalamic nucleus and the motor cortex 
(294–295). In DLB, a reduction of global coherence in 
the alpha band emerges as a consistent finding (296), 
while studies on delta range are equivocal (297). It 
seems feasible that synucleinopathies show similar 
EEG patterns as AD when cognitive deterioration 
is already present which renders the usefulness of 
EEG in the differential diagnosis of AD and PDD/DLB 
questionable. Regarding the prevalence of epileptiform 
patterns in DLB and PDD, no data are available (298).
In summary, there are relatively few studies 
that investigated the utility of EEG/ERP in the 
differential diagnosis of neurocognitive disorders. 
The variability in methods and the lack of systematic 
replication studies offers a mosaic-like landscape of 
results that render synthesis difficult. Nevertheless, 
EEG and ERP biomarkers in AD
200 © 1996-2018
some promising findings suggest that EEG could 
be used to assist AD diagnosis and differentiate it 
from other forms of dementia. The major changes in 
spectral EEG characteristics that seem to be highly 
sensitive in the diagnosis of AD include attenuated 
power in higher frequency bands and increased power 
in lower (delta and theta) bands. Further potentially 
useful indices include altered network characteristics 
(graph analysis), decreased global connectivity, and 
the high prevalence of epileptiform discharges and 
epileptic seizures.
While in AD the most prominent changes 
include an increase in delta power and a decrease 
in alpha power (40–42), the lower frequency bands 
seem to be unaffected in FTD (269) and in depression-
associated cognitive decline (280). Interestingly, 
regarding the alpha and beta frequency bands, spectral 
power show a consistent decrease in AD, FTD, and 
DLB, while there is evidence for increased power in 
these bands in depression-related cognitive decline 
(280). While complexity measures show a consistent 
decrease across all four diseases, connectivity in DLB 
(296), AD (80–81, 84) and FTD (274) share the same 
phenomenology (significant reduction) but depression 
shows increased connectivity (283). Data on the 
prevalence of cognitive-decline associated epileptic 
activity is limited but AD patients are more likely to 
develop epileptic seizures and epileptiform discharges 
(277) (Table 4).
5. CONCLUSIONS AND FUTURE  
PERSPECTIVES
EEG and ERPs allow noninvasive 
assessment of synaptic dysfunction with an extremely 
high temporal resolution (299). AD is suggested to be 
primarily a disorder of synaptic plasticity (128, 300). 
Furthermore altered synaptic plasticity was found 
prior to the appearance of Aβ containing plaques and 
brain atrophy in animal models (301). EEG and ERPs 
primarily reflect synaptic transmission processes, thus 
they seem to be particularly suitable for studying altered 
synaptic plasticity. According to Olinchey and colleges 
ERPs could be even more sensitive to early alterations 
in AD than volumetric MRI (302). It is important to note 
that some studies reviewed here were of poor quality 
and underpowered due to relatively small sample sizes 
indicating a need to adopt stricter methodological 
standards. Nevertheless, our current review suggests 
that EEG/ERP-derived measures of neurotransmission 
definitely deserve further consideration as candidate 
biomarkers in AD, MCI and even preclinical AD. Figure 2 
highlights a small set of promising findings reviewed 
here and areas of potential clinical applications of 
EEG/ERP measures in dementia research in general. 
Regarding further research, we suggest that studies 
are needed that evaluate as many as possible of the 
overviewed spectral markers and ERP components in 
a longitudinal setting, ideally from the pre-symptomatic 
stage with respect to their relative sensitivity and 
specificity. There is an urgent need to standardize ERP 
assessment procedures in order to obtain results that 
allow direct comparisons across different studies and 
laboratories. ERPs might provide robust, cost-effective, 
and easily accessible markers to help diagnosis, track 
disease progression, and evaluate response to therapy, 
thus standardized guidelines for ERP measurements in 
AD are warranted.
The pathologic changes of AD are generally 
deemed to start many years before the initial 
symptoms of cognitive deterioration and the clinical 
diagnosis of dementia (303). There is an urgent need 
to identify the disease in the prodromal or in the early 
clinical phases such as MCI.EEG and ERP methods in 
clinical neurophysiology might serve as important tools 
in the early diagnosis of cognitive dysfunction. These 
methods are easily accessible, non-invasive, relatively 
cheap, and provide objective assessment of synaptic 
neurotransmission underlying sensory and cognitive 
processes. However, although there are several 
promising results, it can be concluded that at the 
moment there is no clinical neurophysiological marker 
or protocol available that could provide a definitive 
diagnosis of dementia.
Table 4. Potential utility of EEG markers in the differential diagnosis of cognitive decline
EEG feature Alzheimer’s disease Frontotemporal dementia Diffuse Lewy-body 
dementia
Depression-related cog-
nitive decline
Delta-power ↑ x ↑ x
Theta-power ↑ x ↑ x
Alpha-power ↓ ↓ ↓ ↑ 
Beta-power ↓ ↓ ↓ ↑ 
Complexity ↓ ↓ ↓ ↓
Connectivity ↓ ↓ ↓ ↑ 
Epileptic activity ↑ ↑ DNA DNA
↑: increase, ↓: decrease, DNA: data not available. Across studies there are clear findings suggesting that most common forms of neurocognitive 
disorders show different EEG characteristics.
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The further development of both experimental 
and clinical neurophysiological methods is important 
and may have the following directions:
5.1. Experimental and analysis methods
Rapid translation of promising experimental 
methods to clinical application is essential. To facilitate 
that it is necessary to increase the dialogue between 
basic science and clinical research.
The development and translation of different 
state-of-art research methods may allow near-
experimental investigations also in clinical settings, 
like invasive EEG recordings for diagnosing hidden 
epileptic activity or to date unknown EEG phenomena.
Modern biophysical modeling tools, such 
as DCMs, allow us to infer hidden parameters of the 
network dynamics underlying the observed EEG/ERP 
signals, and they might allow quantification of the 
status of neurotransmitter systems in specific circuits. 
To improve replicability of findings in the field we 
suggest that future studies should apply preliminary 
power analysis and include samples of sufficient size. 
Furthermore, we emphasize the proper use of EEG/
ERP processing and statistical analysis methods.
5.2. Clinical studies
Quantitative methods should be routinely 
used in the clinical practice of diagnosis and/or 
differential diagnosis of dementias. For this, normative 
databases need to be generated and standardized 
evaluation criteria should be developed. As part of 
this initiative statistical methods for population-based 
analyses (e.g., z-score analysis) should be introduced 
and disseminated. Furthermore, we recommend 
communicating the effect size in future studies in 
addition to statistical significance as it can provide 
information about the practical importance of the 
findings and allow systematic comparisons (meta-
analyses).
To enhance the sensitivity and specificity 
of these methods a promising further step might 
be the combination of various neurophysiological 
tools. Developing combined systems of clinical 
neurophysiology with automatized spectral power, 
coherence, sleep and non-linear analyzing software 
products, could allow examining different parameters 
by one single device. This might be useful in quantifying 
the concordance of different neurophysiological 
abnormalities which, in turn, might increase diagnostic 
efficiency. The alteration of a single neurophysiological 
Figure 2. Examples of promising EEG/ERP findings in AD research and a chart summary of potentially useful methods and markers. A) EEG spectral 
power discriminates between Alzheimer’s and vascular dementia. Mean frequency spectrum over the scalp for each group with absolute frequency. 
Modified with Creative Commons Attribution License from: ref. 272 B) Spectral EEG changes are associated with hippocampus atrophy in MCI and 
AD. Maps show correlation between alpha3/alpha2 frequency band power ratio and volumes of hippocampal subregions in AD patients. Modified with 
Creative Commons Attribution License from: ref. 46 C) Decreased auditory MMN in aMCI compared to healthy elderly in a longitudinal study at t1 and 
t2. Scalp maps show topographical distribution of auditory MMN responses in elderly and aMCI. Modified with Creative Commons Attribution License 
from: ref. 240 D) Patients with MCI and AD show delayed P300 latencies and attenuated P300 amplitudes compared to controls. Modified with Creative 
Commons Attribution License from: ref. 172 E) A summary of existing and emerging methods as well as the main EEG/ERP candidate markers that have 
been used in dementia research. The flowchart highlights the main areas of potential clinical applications of EEG/ERP-derived biomarkers.
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parameter is insufficient for a diagnosis of any type of 
dementia, however if different types of deviations point 
to the same direction, the diagnostic accuracy might 
increase.
To better understand the progressive nature of 
neurodegenerative diseases it is important to perform 
serial longitudinal neurophysiological investigations 
together with neuropsychological testing of healthy 
subjects, starting in their symptom-free youth, to 
identify relationships between neurophysiological 
changes and cognitive decline.
An important aspect of any future direction 
is making the information available for the scientific 
community, for avoiding the reproduction of research 
data and to facilitate progress. The recent revolution in 
cloud-based internet applications has provided us with 
easy-to-use and safe tools to exchange information. 
We encourage data sharing in public databases and 
dissemination of results in open access format should 
facilitate the data sharing between the physicians and 
researchers and distribute the current results more 
efficiently with preferring the open access publication 
methods.
The involvement of descriptive and/or 
quantitative neurophysiological methods in the 
diagnostic protocols of various dementias has outmost 
importance and should be strongly encouraged.
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